Entrada Therapeutics, Inc. 8-K

What Happened

• Entrada Therapeutics, Inc. (TRDA) announced an updated corporate presentation used in investor, analyst and other meetings. The presentation is dated May 18, 2026 and was furnished with a Current Report on Form 8‑K filed May 19, 2026 (Accession No. 0001104659‑26‑063325) under Item 7.01 (Regulation FD Disclosure). The presentation is included as Exhibit 99.1 and is incorporated by reference into the 8‑K.

Key Details

• Filing type: Current Report on Form 8‑K, filed May 19, 2026.
• Disclosure item: Item 7.01 — Regulation FD Disclosure (updated investor presentation).
• Exhibit: Updated corporate presentation furnished as Exhibit 99.1 (presentation dated May 18, 2026).
• No earnings, executive changes, or financial statements were reported in this filing.

Why It Matters

• The update gives investors the company’s latest public messaging about strategy, programs, pipeline and financial positioning as presented to analysts and investors.
• Because it is a Regulation FD disclosure, the presentation is furnished to ensure material information is shared broadly and is part of the company’s public record.
• This 8‑K does not announce earnings, a merger, or management changes — investors should review the attached Exhibit 99.1 for specifics and note any forward‑looking statements the company may include.